News and research before you hear about it on CNBC and others. Claim your 1-week free trial for StreetInsider Premium here.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, the cancer pancreatic and castration-resistant prostate cancer, today announced the appointments of Katherine L. Ruffner, MD, as Chief Medical Officer (CMO) and James E. Levine as Chief Financial Officer (CFO ).
Dr. Ruffner has over 25 years of experience in clinical care, oncology biotechnology, and pharmaceutical drug development. Mr. Levine has extensive investment and investment banking experience in the biotechnology industry, including corporate finance, capital markets and business development. In their newly created roles at Cardiff Oncology, Dr Ruffner will be responsible for overseeing the strategy and execution of clinical programs, as well as identifying and evaluating opportunities for pipeline expansion. In his role as Chief Financial Officer, Mr. Levine will guide Cardiff Oncology’s financial strategy and lead its business development efforts, which will focus on maintaining an optimal financial balance between benefits and risks in each of the company’s programs. . Mr. Levine will also be the principal financial and accounting officer of the Company.
“With these appointments, we have continued to achieve our goal of strengthening our leadership team through the addition of highly talented individuals with complementary skills,” said Mark Erlander, Ph.D., Managing Director of Cardiff Oncology. “They come at a time of significant opportunity and growth for the company, as our core program in KRAS-mutated metastatic colorectal cancer is close to reaching significant clinical milestones and we have a meaningful and exciting platform. new clinical indications on the horizon. Katherine’s extensive experience in clinical oncology care and drug development, including advancing new cancer treatments towards regulatory approval, makes her the perfect fit to lead the development of onvansertib as we work to advance our clinical programs His talents, along with Jamie’s track record in funding clinical-stage biotechnology companies, Leading preclinical and clinical collaborations in business development and business partnerships will be essential to our continued evolution as an e company and our commitment to increasing shareholder value. We are delighted to welcome Katherine and Jamie to our team. “
“Onvansertib, in combination with other cancer treatments, has the potential to address unmet patient needs for a number of critically important cancer indications that are currently underserved by available standard treatments,” said the Dr Ruffner. “I am delighted to join the Cardiff oncology team to advance these important potential new treatment options in an environment that combines a rare blend of the agility of a clinical stage biotech company with the resources, l expertise and thoroughness of a much more mature company. . “
Mr. Levine added: “This is a pivotal time to join Cardiff Oncology. With a strong financial base, a base of healthcare-focused institutional investors, and promising clinical data, the company is well positioned for upcoming clinical and preclinical catalysts. I look forward to working with my new colleagues as we strive to generate shareholder value and, more importantly, meet the medical needs of cancer patients through the continued clinical development of onvansertib. “
Bios of appointees
Dr Ruffner is a United States-trained hematologist / oncologist and brings extensive experience in clinical development and clinical care in oncology, from early clinical phase to post-marketing, both within large companies. pharmaceuticals and specialized biotechnology companies. Most recently, Dr. Ruffner served as Vice President of Clinical Development for ALX Oncology, where she led the strategy and execution of their initial clinical asset on a number of different malignant tumors, both tumors solid and hematologic, and has achieved rapid clinical growth from a single open-label trial in two countries to a program with six global trials in five different cancer indications. Prior to joining ALX, she was Global Clinical Chief Consultant for Lumoxiti at Acerta / Astra Zeneca, and from April 2008 to February 2019, she held several clinical development positions in the field of oncology, most recently as Vice President, Clinical Development for CTI Biopharma, where she oversaw the design of the phase 3 confirmation protocol for pacritinib in myelofibrosis. Previously, Dr. Ruffner was Senior Director, Clinical Development / Medical Affairs for Seattle Genetics, and prior to that, Clinical Head of Immuno-Oncology Agent pidilizumab in Hematologic Malignancies at Medivation. Earlier in his career, Dr. Ruffner worked in clinical development in oncology at Pfizer, Biogen and Amgen in addition to providing clinical care to patients undergoing treatment for hematologic malignancies.
Dr. Ruffner received a BS in Biology from Duke University and an MD from the University of Tennessee. She then completed her residency in internal medicine at the University of Michigan and her oncology fellowship at the University of Washington / Fred Hutchinson Cancer Research Center. Prior to joining the industry, she was an Assistant Professor at Vanderbilt University from 2002-2007 in the Faculty of Hematopoietic Stem Cells.
Mr. Levine joins Cardiff Oncology with extensive experience in merchant and investment banking with private and public biotech and pharmaceutical companies. Prior to joining Cardiff Oncology, Mr. Levine served as CFO of Cidara Therapeutics, where he led the financial aspects of major preclinical and clinical collaborations with Janssen Pharmaceuticals (part of Johnson & Johnson) and Mundipharma with a combined value of over $ 1.3 billion. . Previously, Mr. Levine was President and CEO of Sapphire Energy Inc., a privately held industrial biotechnology company that was sold to two groups of private investors. He also held the same roles at Verenium Corp., where he negotiated six product marketing and asset sales partnerships, before selling the company to BASF. Previously, he was also managing director of the investment banking division of Goldman Sachs & Co., within its healthcare and energy groups.
Mr. Levine holds an MBA in Finance from the Wharton School at the University of Pennsylvania and a BA in Economics from Brandeis University.
Nasdaq Listing Rule 5635 (c) (4) Incentive Grants
In connection with the arrival of Dr Ruffner and Mr Levine at Cardiff Oncology, the board of directors of the company has approved the grant of non-qualifying stock options for the purchase of 200,000 and 390,000 common shares of Cardiff Oncology, respectively, outside of Cardiff Oncology 2021. Stock Omnibus Incentive Plan. The stock options were granted as significant incentives for Dr Ruffner and Mr Levine to become employees of Cardiff Oncology in accordance with Nasdaq listing rule 5635 (c) (4). The options were granted to Dr. Ruffner and Mr. Levine on July 12, 2021 and have an exercise price of $ 6.55 per share, which is the closing price of Cardiff Oncology common stock on the day immediately preceding the Date of grant. Options vest over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the next 36 months, subject to the continued employment of Dr. Ruffner and Mr. Levine at Cardiff Oncology on those dates. acquisition.